We are excited to be able to share the following article provided by a member of the GRACE Fellows Ambassador Program, Dr. Arjun Gupta. The article...
VIDEOS
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
GRACE is excited to bring to you more in our new series on surviving with cancer GRACE is excited to bring to you more in our series on surviving with...
ARTICLES
Dr. Jack West asks the question of whether newer, more active ALK inhibitors such as alectinib should be used as first line therapy rather than for acquired resistance, including introducing the ALEX trial that is trying to answer this question.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Dr. Jack West introduces the question of whether third generation EGFR tyrosine kinase inhibitors osimertinib and rociletinib should be used as first line therapy rather than for acquired resistance, including discussing key clinical trials on the topic.
Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.